查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1593906

溶小體貯積症市場：按疾病類型、治療類型和最終用戶分類 - 全球預測 2025-2030

Lysosomal Storage Diseases Market by Disease Type (Fabry Diseases, Gaucher's Diseases, Mucopolysaccharidosis), Type of Therapy (Enzyme Replacement Therapy, Stem Cell Therapy, Substrate Reduction Therapy), End User - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 189 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2023年溶小體貯積症市場價值為93.1億美元，預計到2024年將達到99.8億美元，複合年成長率為7.48%，到2030年將達到154.3億美元。

溶小體貯積症（LSD）是一組罕見的代謝性疾病，其特徵是酵素缺乏，未消化的大分子在溶小體中積聚。鑑於這些疾病的嚴重性及其對患者生活品質的影響，迫切需要加強診斷、治療和治療提供方法。主要應用是酵素替代療法（ERT）、基材減少療法和基因療法。最終用戶範圍從專業醫療機構到專門研究罕見疾病的研究機構。市場成長是由人們對罕見疾病的認知不斷提高、研究成本不斷上升以及基因組研究的進步所推動的。主要影響因素包括生物技術投資的增加以及支持孤兒藥開發的有利政府政策框架。利用 CRISPR 和其他基因編輯技術可能會為 LSD開拓新的治療方法。此外，製藥公司和研究機構之間的合作加速了創新。然而，高昂的治療費用、嚴格的監管和有限的患者群等限制因素可能會阻礙大規模投資。財務永續性、負擔能力和治療方法的可近性仍然是挑戰。藥物輸送系統的創新以及個人化醫療人工智慧的整合是提高治療效果和患者預後的有希望的途徑。市場洞察表明，對利基技術進步、策略夥伴關係以及研發的投資對於抓住新機會至關重要。儘管市場主要由現有的治療方法定義，但目前正在轉向下一代治療方法，包括基因治療和個人化醫療。相關人員應專注於協作方法和以患者為中心的解決方案，以應對這一複雜的情況並實現永續成長。透過促進創新和提高全球意識，該行業可以解決現有的局限性，並推動新興但不斷發展的溶酶體貯積症領域的市場大幅擴張。

主要市場統計
基準年[2023] 93.1億美元
預測年份 [2024] 99.8億美元
預測年份 [2030] 154.3億美元
複合年成長率（%） 7.48%

市場動態：快速發展的溶小體貯積症市場的關鍵市場洞察

供需的動態交互作用正在改變溶小體貯積症市場。透過了解這些不斷變化的市場動態，公司可以準備好做出明智的投資決策、完善策略決策並抓住新的商機。全面了解這些趨勢可以幫助企業降低政治、地理、技術、社會和經濟領域的風險，同時消費行為及其對製造成本的影響以及對採購趨勢的影響。

  • 市場促進因素
    • 溶小體貯積症的全球盛行率
    • 傾向於疾病的早期診斷和治療
    • 增加酵素替代療法的使用
  • 市場限制因素
    • 治療溶小體貯積症相關的高成本
  • 市場機會
    • 基因編輯技術和基因治療的進展
    • 治療溶小體貯積症的個人化醫療方法的出現
  • 市場挑戰
    • 溶小體儲存藥物核准的嚴格法律規範

波特五力：駕馭溶小體貯積症市場的策略工具

波特的五力框架是理解市場競爭格局的重要工具。波特的五力框架為評估公司的競爭地位和探索策略機會提供了清晰的方法。該框架可幫助公司評估市場動態並確定新業務的盈利。這些見解使公司能夠利用自己的優勢，解決弱點並避免潛在的挑戰，從而確保更強大的市場地位。

PESTLE分析：了解對溶小體貯積症市場的外部影響

外部宏觀環境因素在塑造溶小體貯積症市場的績效動態方面發揮著至關重要的作用。對政治、經濟、社會、技術、法律和環境因素的分析提供了應對這些影響所需的資訊。透過調查 PESTLE 因素，公司可以更了解潛在的風險和機會。這種分析可以幫助公司預測法規、消費者偏好和經濟趨勢的變化，並為他們做出積極主動的決策做好準備。

市場佔有率分析 了解溶小體貯積症市場的競爭狀況

溶小體貯積症市場的詳細市場佔有率分析可以對供應商的績效進行全面評估。公司可以透過比較收益、客戶群和成長率等關鍵指標來揭示其競爭地位。該分析揭示了市場集中、分散和整合的趨勢，為供應商提供了製定策略決策所需的見解，以應對日益激烈的競爭。

FPNV 定位矩陣溶小體貯積症市場供應商的績效評估

FPNV 定位矩陣是評估溶小體貯積症市場供應商的關鍵工具。此矩陣允許業務組織根據供應商的商務策略和產品滿意度評估供應商，從而做出符合其目標的明智決策。這四個象限使您能夠清晰、準確地分類供應商，以確定最能滿足您的策略目標的合作夥伴和解決方案。

策略分析和建議描繪了溶小體貯積症市場的成功之路

對於旨在加強其在全球市場的影響力的公司來說，對溶小體貯積症市場的策略分析至關重要。透過考慮關鍵資源、能力和績效指標，公司可以識別成長機會並努力改進。這種方法使您能夠克服競爭環境中的挑戰，利用新的商機，並取得長期成功。

本報告提供了涵蓋關鍵重點領域的市場全面分析：

1. 市場滲透率：對當前市場環境的詳細審查、主要企業的廣泛資料、對其在市場中的影響力和整體影響力的評估。

2. 市場開拓：辨識新興市場的成長機會，評估現有領域的擴張潛力，並提供未來成長的策略藍圖。

3. 市場多元化：分析近期產品發布、開拓地區、關鍵產業進展、塑造市場的策略投資。

4. 競爭評估與情報：徹底分析競爭格局，檢驗市場佔有率、業務策略、產品系列、認證、監管核准、專利趨勢、主要企業的技術進步等。

5. 產品開發與創新：重點在於有望推動未來市場成長的最尖端科技、研發活動和產品創新。

我們也回答重要問題，以幫助相關人員做出明智的決策：

1.目前的市場規模和未來的成長預測是多少？

2. 哪些產品、區隔市場和地區提供最佳投資機會？

3.塑造市場的主要技術趨勢和監管影響是什麼？

4.主要廠商的市場佔有率和競爭地位如何？

5. 推動供應商市場進入和退出策略的收益來源和策略機會是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 全球溶小體貯積症的盛行率
      • 疾病的早​​期診斷和治療趨勢
      • 增加酵素替代療法的使用
    • 抑制因素
      • T-溶小體儲積症的治療費用高昂
    • 機會
      • 基因編輯技術和基因治療的進展
      • 治療溶小體儲積症的個人化醫療方法的出現
    • 任務
      • 溶小體儲存藥物核准的嚴格法規結構
  • 市場區隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 經濟
    • 社群
    • 技術的
    • 合法地
    • 環境

第6章溶小體貯積症市場：依疾病類型

  • 法布瑞氏症
  • 高雪氏症
  • 黏多醣症
  • 龐貝氏症候群

第7章依治療類型分類的溶小體貯積症市場

  • 酵素替代療法
  • 幹細胞療法
  • 基材減少療法

第8章溶小體貯積症市場：依最終用戶分類

  • 診所
  • 醫院

第9章北美及南美溶小體貯積症市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第10章亞太地區溶小體貯積症市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第11章歐洲、中東和非洲溶小體貯積症市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第12章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
  • 戰略分析和建議

公司名單

  • Abeona Therapeutics Inc.
  • Alexion Pharmaceuticals, Inc.
  • Amicus Therapeutics
  • ArmaGen, Inc.
  • BioMarin
  • CHIESI USA, Inc.
  • Denali Therapeutics Inc.
  • Freeline Therapeutics
  • Homology Medicines, Inc.
  • Horizon Pharma PLC
  • Idorsia Pharmaceuticals Ltd.
  • JCR Pharmaceuticals Co., Ltd.
  • Lysogene
  • Neurogene Inc.
  • Novartis AG
  • Orchard Therapeutics Limited
  • Pfizer Inc.
  • Protalix
  • Sangamo Therapeutics, Inc.
  • Sanofi SA
  • Spark Therapeutics, Inc.
  • Swedish Orphan Biovitrum AB
  • Takeda Pharmaceutical Company Limited
  • Ultragenyx Pharmaceutical Inc.
Product Code: MRR-DD0700E81E5B

The Lysosomal Storage Diseases Market was valued at USD 9.31 billion in 2023, expected to reach USD 9.98 billion in 2024, and is projected to grow at a CAGR of 7.48%, to USD 15.43 billion by 2030.

Lysosomal Storage Diseases (LSDs) are a group of rare metabolic disorders characterized by an enzyme deficiency, leading to the accumulation of undigested macromolecules in lysosomes. Given the severe nature of these diseases and their impact on patient quality of life, there is a pressing necessity for enhanced diagnostics, treatments, and therapeutic delivery methods. The primary application revolves around enzyme replacement therapy (ERT), substrate reduction therapy, and gene therapy. End-users range from specialized healthcare facilities to research institutions dedicated to orphan diseases. The market growth is driven by increasing awareness, rising healthcare spending in rare diseases, and advancements in genomic research. Key influencers include growing investments in biotechnology and favorable government policy frameworks supporting orphan drug development. Opportunities lie in leveraging CRISPR and other gene-editing technologies to pioneer novel treatment approaches for LSDs. Additionally, collaborations between pharmaceutical companies and research institutions can accelerate innovation. However, limitations persist due to the high cost of treatment, stringent regulatory barriers, and the limited patient pool, which might deter large-scale investments. Financial sustainability, affordability, and accessibility of therapies remain challenging. Innovating in drug delivery systems and integrating artificial intelligence for personalized medicine are promising avenues to enhance treatment efficacy and patient outcomes. Market insights suggest that niche technological advancements, strategic partnerships, and investment in R&D are critical for capturing emerging opportunities. Although the market is primarily defined by established treatments, there is a pivot towards next-gen therapies involving gene and personalized medicine. Stakeholders should focus on collaborative approaches and patient-centric solutions to navigate the complex landscape, aiming for sustainable growth. By fostering innovation and enhancing global awareness, the industry can address existing limitations and propel significant market expansion in the nascent but evolving field of lysosomal storage diseases.

KEY MARKET STATISTICS
Base Year [2023] USD 9.31 billion
Estimated Year [2024] USD 9.98 billion
Forecast Year [2030] USD 15.43 billion
CAGR (%) 7.48%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Lysosomal Storage Diseases Market

The Lysosomal Storage Diseases Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Prevalence of lysosomal storage disorders worldwide
    • Inclination toward early diagnosis and treatment of diseases
    • Increasing use of enzyme replacement therapies
  • Market Restraints
    • High cost associated with the treatment of t lysosomal storage disease
  • Market Opportunities
    • Advancements in gene editing technologies and gene therapies
    • Emergence of personalized medicine approach to treat lysosomal storage conditions
  • Market Challenges
    • Stringent regulatory framework for approval of lysosomal storage drugs

Porter's Five Forces: A Strategic Tool for Navigating the Lysosomal Storage Diseases Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Lysosomal Storage Diseases Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Lysosomal Storage Diseases Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Lysosomal Storage Diseases Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Lysosomal Storage Diseases Market

A detailed market share analysis in the Lysosomal Storage Diseases Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Lysosomal Storage Diseases Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Lysosomal Storage Diseases Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Lysosomal Storage Diseases Market

A strategic analysis of the Lysosomal Storage Diseases Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Lysosomal Storage Diseases Market, highlighting leading vendors and their innovative profiles. These include Abeona Therapeutics Inc., Alexion Pharmaceuticals, Inc., Amicus Therapeutics, ArmaGen, Inc., BioMarin, CHIESI USA, Inc., Denali Therapeutics Inc., Freeline Therapeutics, Homology Medicines, Inc., Horizon Pharma PLC, Idorsia Pharmaceuticals Ltd., JCR Pharmaceuticals Co., Ltd., Lysogene, Neurogene Inc., Novartis AG, Orchard Therapeutics Limited, Pfizer Inc., Protalix, Sangamo Therapeutics, Inc., Sanofi S.A., Spark Therapeutics, Inc., Swedish Orphan Biovitrum AB, Takeda Pharmaceutical Company Limited, and Ultragenyx Pharmaceutical Inc..

Market Segmentation & Coverage

This research report categorizes the Lysosomal Storage Diseases Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Disease Type, market is studied across Fabry Diseases, Gaucher's Diseases, Mucopolysaccharidosis, and Pompe's Syndrome.
  • Based on Type of Therapy, market is studied across Enzyme Replacement Therapy, Stem Cell Therapy, and Substrate Reduction Therapy.
  • Based on End User, market is studied across Clinics and Hospitals.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Prevalence of lysosomal storage disorders worldwide
      • 5.1.1.2. Inclination toward early diagnosis and treatment of diseases
      • 5.1.1.3. Increasing use of enzyme replacement therapies
    • 5.1.2. Restraints
      • 5.1.2.1. High cost associated with the treatment of t lysosomal storage disease
    • 5.1.3. Opportunities
      • 5.1.3.1. Advancements in gene editing technologies and gene therapies
      • 5.1.3.2. Emergence of personalized medicine approach to treat lysosomal storage conditions
    • 5.1.4. Challenges
      • 5.1.4.1. Stringent regulatory framework for approval of lysosomal storage drugs
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Lysosomal Storage Diseases Market, by Disease Type

  • 6.1. Introduction
  • 6.2. Fabry Diseases
  • 6.3. Gaucher's Diseases
  • 6.4. Mucopolysaccharidosis
  • 6.5. Pompe's Syndrome

7. Lysosomal Storage Diseases Market, by Type of Therapy

  • 7.1. Introduction
  • 7.2. Enzyme Replacement Therapy
  • 7.3. Stem Cell Therapy
  • 7.4. Substrate Reduction Therapy

8. Lysosomal Storage Diseases Market, by End User

  • 8.1. Introduction
  • 8.2. Clinics
  • 8.3. Hospitals

9. Americas Lysosomal Storage Diseases Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Lysosomal Storage Diseases Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Lysosomal Storage Diseases Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. Market Share Analysis, 2023
  • 12.2. FPNV Positioning Matrix, 2023
  • 12.3. Competitive Scenario Analysis
  • 12.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Abeona Therapeutics Inc.
  • 2. Alexion Pharmaceuticals, Inc.
  • 3. Amicus Therapeutics
  • 4. ArmaGen, Inc.
  • 5. BioMarin
  • 6. CHIESI USA, Inc.
  • 7. Denali Therapeutics Inc.
  • 8. Freeline Therapeutics
  • 9. Homology Medicines, Inc.
  • 10. Horizon Pharma PLC
  • 11. Idorsia Pharmaceuticals Ltd.
  • 12. JCR Pharmaceuticals Co., Ltd.
  • 13. Lysogene
  • 14. Neurogene Inc.
  • 15. Novartis AG
  • 16. Orchard Therapeutics Limited
  • 17. Pfizer Inc.
  • 18. Protalix
  • 19. Sangamo Therapeutics, Inc.
  • 20. Sanofi S.A.
  • 21. Spark Therapeutics, Inc.
  • 22. Swedish Orphan Biovitrum AB
  • 23. Takeda Pharmaceutical Company Limited
  • 24. Ultragenyx Pharmaceutical Inc.

LIST OF FIGURES

  • FIGURE 1. LYSOSOMAL STORAGE DISEASES MARKET RESEARCH PROCESS
  • FIGURE 2. LYSOSOMAL STORAGE DISEASES MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL LYSOSOMAL STORAGE DISEASES MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY DISEASE TYPE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY DISEASE TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY TYPE OF THERAPY, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY TYPE OF THERAPY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY END USER, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY END USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. AMERICAS LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 13. AMERICAS LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. UNITED STATES LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 15. UNITED STATES LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. ASIA-PACIFIC LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. ASIA-PACIFIC LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. EUROPE, MIDDLE EAST & AFRICA LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. LYSOSOMAL STORAGE DISEASES MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 21. LYSOSOMAL STORAGE DISEASES MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. LYSOSOMAL STORAGE DISEASES MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL LYSOSOMAL STORAGE DISEASES MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. LYSOSOMAL STORAGE DISEASES MARKET DYNAMICS
  • TABLE 7. GLOBAL LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY FABRY DISEASES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY GAUCHER'S DISEASES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY MUCOPOLYSACCHARIDOSIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY POMPE'S SYNDROME, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY ENZYME REPLACEMENT THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY STEM CELL THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY SUBSTRATE REDUCTION THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. AMERICAS LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 20. AMERICAS LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
  • TABLE 21. AMERICAS LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 22. AMERICAS LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 23. ARGENTINA LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 24. ARGENTINA LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
  • TABLE 25. ARGENTINA LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 26. BRAZIL LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 27. BRAZIL LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
  • TABLE 28. BRAZIL LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 29. CANADA LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 30. CANADA LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
  • TABLE 31. CANADA LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 32. MEXICO LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 33. MEXICO LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
  • TABLE 34. MEXICO LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 35. UNITED STATES LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 36. UNITED STATES LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
  • TABLE 37. UNITED STATES LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 38. UNITED STATES LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 39. ASIA-PACIFIC LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 40. ASIA-PACIFIC LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
  • TABLE 41. ASIA-PACIFIC LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 42. ASIA-PACIFIC LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 43. AUSTRALIA LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 44. AUSTRALIA LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
  • TABLE 45. AUSTRALIA LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 46. CHINA LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 47. CHINA LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
  • TABLE 48. CHINA LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 49. INDIA LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 50. INDIA LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
  • TABLE 51. INDIA LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 52. INDONESIA LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 53. INDONESIA LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
  • TABLE 54. INDONESIA LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 55. JAPAN LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 56. JAPAN LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
  • TABLE 57. JAPAN LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 58. MALAYSIA LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 59. MALAYSIA LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
  • TABLE 60. MALAYSIA LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 61. PHILIPPINES LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 62. PHILIPPINES LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
  • TABLE 63. PHILIPPINES LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 64. SINGAPORE LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 65. SINGAPORE LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
  • TABLE 66. SINGAPORE LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 67. SOUTH KOREA LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 68. SOUTH KOREA LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
  • TABLE 69. SOUTH KOREA LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 70. TAIWAN LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 71. TAIWAN LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
  • TABLE 72. TAIWAN LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 73. THAILAND LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 74. THAILAND LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
  • TABLE 75. THAILAND LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 76. VIETNAM LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 77. VIETNAM LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
  • TABLE 78. VIETNAM LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 79. EUROPE, MIDDLE EAST & AFRICA LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 80. EUROPE, MIDDLE EAST & AFRICA LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
  • TABLE 81. EUROPE, MIDDLE EAST & AFRICA LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 82. EUROPE, MIDDLE EAST & AFRICA LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 83. DENMARK LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 84. DENMARK LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
  • TABLE 85. DENMARK LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 86. EGYPT LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 87. EGYPT LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
  • TABLE 88. EGYPT LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 89. FINLAND LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 90. FINLAND LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
  • TABLE 91. FINLAND LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 92. FRANCE LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 93. FRANCE LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
  • TABLE 94. FRANCE LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 95. GERMANY LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 96. GERMANY LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
  • TABLE 97. GERMANY LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 98. ISRAEL LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 99. ISRAEL LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
  • TABLE 100. ISRAEL LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 101. ITALY LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 102. ITALY LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
  • TABLE 103. ITALY LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 104. NETHERLANDS LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 105. NETHERLANDS LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
  • TABLE 106. NETHERLANDS LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 107. NIGERIA LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 108. NIGERIA LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
  • TABLE 109. NIGERIA LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 110. NORWAY LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 111. NORWAY LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
  • TABLE 112. NORWAY LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 113. POLAND LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 114. POLAND LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
  • TABLE 115. POLAND LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 116. QATAR LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 117. QATAR LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
  • TABLE 118. QATAR LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 119. RUSSIA LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 120. RUSSIA LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
  • TABLE 121. RUSSIA LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 122. SAUDI ARABIA LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 123. SAUDI ARABIA LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
  • TABLE 124. SAUDI ARABIA LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 125. SOUTH AFRICA LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 126. SOUTH AFRICA LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
  • TABLE 127. SOUTH AFRICA LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 128. SPAIN LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 129. SPAIN LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
  • TABLE 130. SPAIN LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 131. SWEDEN LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 132. SWEDEN LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
  • TABLE 133. SWEDEN LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 134. SWITZERLAND LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 135. SWITZERLAND LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
  • TABLE 136. SWITZERLAND LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 137. TURKEY LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 138. TURKEY LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
  • TABLE 139. TURKEY LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 140. UNITED ARAB EMIRATES LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 141. UNITED ARAB EMIRATES LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
  • TABLE 142. UNITED ARAB EMIRATES LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 143. UNITED KINGDOM LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 144. UNITED KINGDOM LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
  • TABLE 145. UNITED KINGDOM LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 146. LYSOSOMAL STORAGE DISEASES MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 147. LYSOSOMAL STORAGE DISEASES MARKET, FPNV POSITIONING MATRIX, 2023